US Patent Issued to Pharmacosmos Holding on April 29 for "Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors" (North Carolina Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,431, issued on April 29, was assigned to Pharmacosmos Holding A/S (Holbaek, Denmark).

"Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors" was invented by Jay Copeland Strum (Hillsborough, N.C.), John E. Bisi (Apex, N.C.), Patrick Joseph Roberts (Durham, N.C.) and Jessica A. Sorrentino (Durham, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitor...